drugset
Drugs / FAP-2286
last change Sep 2025 re-read 3 minutes ago

FAP-2286

Diagnostic / imaging agent targets FAP

Investigated by
Society of Abdominal Radiology · Thomas Hope · Yi Tian

Trials 2

today NCT07144085 · Ph 1 NCT04621435 · Ph 1
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07144085 Sep 2025 → Jul 2027 expected metastatic malignant neoplasm Yi Tian Recruiting No outcome recorded
Phase 1 NCT04621435 Dec 2020 → Dec 2026 expected metastatic malignant neoplasm Thomas Hope Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2022-12-22 3B Pharmaceuticals GmbH 3BP company statement re recent events involving Clovis Oncology and FAP-2286 3b-pharma.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as FAP-2286 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04621435 ↗
1

NCT07144085 ↗
Modality Diagnostic / imaging agent “PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FXX489 or 68Ga-FAP-2286 or 18F-FDG.” NCT07144085 ↗
Route Intravenous “given intravenously at a single time prior to imaging” NCT04621435 ↗
Target FAP “binds to Fibroblast Activation Protein (FAP)” NCT04621435 ↗